IL-10Rβ Inhibitors
IL-10Rβ inhibitors represent a diverse class of compounds that act either directly on IL-10Rβ or indirectly by modulating key signaling pathways intricately connected to IL-10Rβ function. Tofacitinib, Ruxolitinib, and Baricitinib exemplify indirect inhibitors by targeting Janus kinases (JAKs), specifically JAK1 and JAK2. These inhibitors disrupt IL-10Rβ signaling cascades by interfering with JAK-dependent regulation, affecting IL-10Rβ activation and subsequent cellular responses. Additionally, Tocilizumab, a monoclonal antibody targeting the interleukin-6 (IL-6) receptor, indirectly modulates IL-10Rβ signaling by disrupting crosstalk between IL-6 and IL-10Rβ pathways. This interference with the IL-6-mediated regulation of IL-10Rβ influences its activation and downstream cellular responses. The JAK inhibitors Filgotinib, Momelotinib, and Fedratinib further illustrate the indirect modulation of IL-10Rβ by selectively inhibiting JAK1 or JAK2. These compounds disrupt IL-10Rβ signaling cascades by interfering with JAK-dependent regulation, impacting IL-10Rβ activation and cellular responses.
SB431542 and LY-364947 showcase indirect inhibition by targeting the transforming growth factor-beta (TGF-β) signaling pathway. These inhibitors disrupt crosstalk between TGF-β and IL-10Rβ pathways, influencing IL-10Rβ activation and downstream cellular responses. SB203580 and AZD7762 indirectly inhibit IL-10Rβ by targeting the p38 mitogen-activated protein kinase (MAPK) and checkpoint kinase 1 (CHK1), respectively. These compounds interfere with the downstream signaling cascades involving IL-10Rβ, affecting its activation and cellular responses. Furthermore, LY-2157299, a TGF-β receptor inhibitor, indirectly modulates IL-10Rβ signaling by disrupting crosstalk between TGF-β and IL-10Rβ pathways. This interference with the TGF-β-mediated regulation of IL-10Rβ impacts its activation and downstream cellular responses. In summary, IL-10Rβ inhibitors comprise both direct and indirect modulators, providing a nuanced approach to interfere with IL-10Rβ signaling and its associated cellular responses.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib is another JAK inhibitor that indirectly inhibits IL-10Rβ by targeting JAK1 and JAK2. By inhibiting these kinases, Ruxolitinib disrupts the activation of IL-10Rβ signaling cascades, indirectly modulating its function. This indirect inhibition occurs through the interference with the JAK-dependent regulation of IL-10Rβ, affecting its activation and the subsequent cellular responses influenced by IL-10Rβ signaling. | ||||||
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $196.00 $651.00 | ||
Baricitinib is a selective JAK1 and JAK2 inhibitor that indirectly modulates IL-10Rβ signaling. By inhibiting these kinases, Baricitinib disrupts the downstream signaling cascades involving IL-10Rβ, indirectly influencing its function. This indirect modulation occurs through the interference with the JAK-dependent regulation of IL-10Rβ, affecting its activation and the subsequent cellular responses influenced by IL-10Rβ signaling. | ||||||
Filgotinib | 1206161-97-8 | sc-507393 | 10 mg | $150.00 | ||
Filgotinib is a JAK1 inhibitor that indirectly modulates IL-10Rβ signaling. By selectively inhibiting JAK1, Filgotinib disrupts the downstream signaling cascades involving IL-10Rβ, indirectly influencing its function. This indirect modulation occurs through the interference with the JAK1-dependent regulation of IL-10Rβ, affecting its activation and the subsequent cellular responses influenced by IL-10Rβ signaling. | ||||||
Cyt387 | 1056634-68-4 | sc-364733 sc-364733A | 10 mg 50 mg | $210.00 $600.00 | 2 | |
Momelotinib (Cyt387) is a JAK1 and JAK2 inhibitor that indirectly inhibits IL-10Rβ by targeting these kinases. By inhibiting JAK1 and JAK2, Momelotinib disrupts the activation of IL-10Rβ signaling cascades, indirectly modulating its function. This indirect inhibition occurs through the interference with the JAK-dependent regulation of IL-10Rβ, affecting its activation and the subsequent cellular responses influenced by IL-10Rβ signaling. | ||||||
TG101348 | 936091-26-8 | sc-364740 sc-364740A | 5 mg 25 mg | $207.00 $515.00 | 6 | |
Fedratinib (TG101348) is another JAK2 inhibitor that indirectly modulates IL-10Rβ signaling. By inhibiting JAK2, Fedratinib disrupts the downstream signaling cascades involving IL-10Rβ, indirectly influencing its function. This indirect modulation occurs through the interference with the JAK2-dependent regulation of IL-10Rβ, affecting its activation and the subsequent cellular responses influenced by IL-10Rβ signaling. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542 indirectly inhibits IL-10Rβ by targeting the transforming growth factor-beta (TGF-β) signaling pathway. By inhibiting the TGF-β receptor, SB431542 disrupts the crosstalk between TGF-β and IL-10Rβ signaling pathways, indirectly modulating IL-10Rβ function. This indirect modulation occurs through the interference with the TGF-β-mediated regulation of IL-10Rβ, affecting its activation and the subsequent cellular responses influenced by IL-10Rβ signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 indirectly inhibits IL-10Rβ by targeting the p38 mitogen-activated protein kinase (MAPK) signaling pathway. By inhibiting p38 MAPK, SB203580 disrupts the downstream signaling cascades involving IL-10Rβ, indirectly influencing its function. This indirect modulation occurs through the interference with the p38 MAPK-dependent regulation of IL-10Rβ, affecting its activation and the subsequent cellular responses influenced by IL-10Rβ signaling. | ||||||
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $105.00 $153.00 | 4 | |
LY-364947 is a selective inhibitor of the TGF-β receptor that indirectly modulates IL-10Rβ signaling. By inhibiting the TGF-β receptor, LY-364947 disrupts the crosstalk between TGF-β and IL-10Rβ signaling pathways, indirectly influencing IL-10Rβ function. This indirect modulation occurs through the interference with the TGF-β-mediated regulation of IL-10Rβ, affecting its activation and the subsequent cellular responses influenced by IL-10Rβ signaling. | ||||||
AZD7762 | 860352-01-8 | sc-364423 | 2 mg | $107.00 | ||
AZD7762 is a checkpoint kinase (CHK1) inhibitor that indirectly influences IL-10Rβ signaling. By inhibiting CHK1, AZD7762 disrupts the downstream signaling cascades involving IL-10Rβ, indirectly modulating its function. This indirect modulation occurs through the interference with the CHK1-dependent regulation of IL-10Rβ, affecting its activation and the subsequent cellular responses influenced by IL-10Rβ signaling. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $209.00 $352.00 | 3 | |
LY-2157299 is a TGF-β receptor inhibitor that indirectly inhibits IL-10Rβ by targeting the TGF-β signaling pathway. By inhibiting the TGF-β receptor, LY-2157299 disrupts the crosstalk between TGF-β and IL-10Rβ signaling pathways, indirectly modulating IL-10Rβ function. This indirect inhibition occurs through the interference with the TGF-β-mediated regulation of IL-10Rβ, affecting its activation and the subsequent cellular responses influenced by IL-10Rβ signaling. | ||||||